Cipla shares ratings cut by Morgan Stanley, CLSA on earnings
Reuters: Mumbai, Feb 07 2013, 11:48 IST
Morgan Stanley and CLSA downgraded their ratings on Cipla Ltd shares a day after the Indian drugmaker reported a slower-than-expected rise in its October-December net profit.
Morgan Stanley cut its ratings to "equal-weight" from "overweight", citing slower growth prospects on the back of limited niche drug launches, lower margins and a higher tax rate. The bank also cut its price target to 414 rupees from 437 rupees.
CLSA cut its ratings on Cipla to "underperform" from "outperform", citing disappointing margins in the October-December quarter and expectations near-term earnings growth will be slower due a higher base. The bank cut its price target to 415 rupees from 475 rupees.
Previous Story Jet Airways, SpiceJet, Air India talk to Boeing for 737 replacement MAX: Dinesh Keskar Next Story Address core concerns to encourage investment: USIBC to FM
Reader's Comments| Post a Comment
Be the first to comment.
